Active substanceCefoperazone + SulbactamCefoperazone + Sulbactam
Similar drugsTo uncover
  • Bakperazone
    powder w / m in / in 
  • Baktsefort
    powder w / m in / in 
    KRASFARMA, JSC     Russia
  • Sulzencef®
    powdersolution w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Sulmover®
    powdersolution w / m in / in 
  • Sulmover®
    powdersolution w / m in / in 
  • Sulperazone
    powdersolution w / m in / in 
  • SULPERATEF®
    powdersolution w / m in / in 
    ABOLMED, LLC     Russia
  • Sulceph
    powdersolution w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Cebanex
    powdersolution w / m in / in 
  • Cebanex
    powdersolution w / m in / in 
  • Cefbactam®
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Cefoperazone and Sulbactam Jodas
    powdersolution w / m in / in 
    JODAS EKSPOIM, LLC     Russia
  • Cefoperazone and Sulbactam Spencer
    powdersolution w / m in / in 
    Spencer Pharma UK Limited     United Kingdom
  • Cefpar SV
    powdersolution w / m in / in 
  • Dosage form: & nbsp
    powder for solution for intravenous and intramuscular administration
    Composition:
    Active substances: one vial contains Cefoperazone sodium (equivalent to cefoperazone) 250 mg, 500 mg, 1000 mg and Sulbactam sodium (equivalent to sulbactam) 250 mg, 500 mg, 1000 mg.
    Description:White or white with a yellowish tint powder.
    Pharmacotherapeutic group:Antibiotic - cephalosporin + beta-lactamase inhibitor
    ATX: & nbsp

    J.01.D.D.62   Cefoperazone in combination with other drugs

    Pharmacodynamics:
    Combined drug.
    Cephalosporin III generation in combination with a beta-lactamase inhibitor. Cefoperazone - a semi-synthetic cephalosporin antibiotic of broad spectrum, intended only for parenteral use. It acts on sensitive microorganisms during their active propagation by inhibiting the biosynthesis of the mucopeptide of the cell wall.
    Sulbactam is a derivative of penicillanic acid. It is an irreversible inhibitor of beta-lactamases. Sulbactam does not have clinically significant antibacterial activity (with the exception of Neisseriae and Acinetobacter).
    The ability of sulbactam to prevent the destruction of penicillins and cephalosporins by resistant microorganisms has been confirmed in studies using resistant strains,in respect of which sulbactam possessed a pronounced synergism with penicillins and cephalosporins. Sulbactam binds to some penicillin-binding proteins, so cefoperazone + sulbactam often has a more pronounced effect on sensitive strains than one cefoperazone. Cefoperazone + sulbactam is active against all microorganisms sensitive to cefonerazone. In addition, it has a synergistic effect on the following microorganismsbasics: Haemophilus influenzae, Bacteroides spp., Staphylococcus spp., Acinetobacter fromalcoaceticus, Enterobacter aerogenes, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Morganella morganii, Citrobacier freundii, Enterobacter cloacae, Citrobacter diversus.

    Active in viiro for a wide range of microorganisms:

    grimpositive bacteria - Staphylococcus aureus (including strains that form and do not form penicillinase). Staphylococcus epidermidis, Streptococcus pneumoniae. Streptococcus pyogenes (beta-hemolytic strain of the group A). Streptococcus agalactiae (beta-hemolytic strain of group B), most strains of beta-hemolytic Streptococcus spp., Enterococcus faecalis:

    gram-negative bacteria - Escherichia coli. Klebsiella spp.. Enterobacter spp., Ciirobacier spp. Haemophilus influenzae, Proteus mirabilis. Morganella morganii, Providencia rettgeri. Providencia spp., Serratia spp. (including Serratia marcescens). Salmonella spp .. Shigella spp .. Pseudomonas aeruginosa. Acinetobacter calcoaceticus. Neisseria gonorrhoeae. Neisseria meningitidis: Bordetella pertussis. Yersinia enterocolitica;

    anaerobic bacteria - Bacteroides fragilis. Fusobacterium spp. Peptococcus spp. Peptostreptococcus spp. Veillonella spp., Clostridium spp. Eubacter spp. Lactobacillus spp.

    Pharmacokinetics:
    The maximum concentration (Cmax) of sulbactam and cefoperazone after intravenous (iv) administration of Bakperazone in a dose of 2 g (1 g of sulbactam, 1 g of cefoperazone) is achieved within 5 minutes and averages 130.2 and 236.8 μg / ml, respectively .This reflects a higher volume of distribution (Vd) of sulbactam (from 8.0 to 27.6 liters) compared with that of cefoperazone (from 10.2 to 11.3 liters).
    Both sulbactam and cefoperazone well distributed in various tissues and body fluids, including bile, gall bladder, skin, appendix, fallopian tubes, ovaries, uterus.
    With repeated use of significant changes in the pharmacokinetic parameters of both components was not noted. When the drug was administered every 8-12 h, cumulation was not observed.
    Approximately 84% of the dose of sulbactam and 25% of the dose of cefoperazone are excreted by the kidneys. The rest of cefoperazone is excreted mainly with bile. The half-life period (T1 / 2) of sulbactam averages about 1 hour. T1 / 2 of cefoperazone is 1.7 hours.
    Pharmacokinetics in special clinical cases
    In patients with varying degrees of renal dysfunction, a high correlation was found between the overall clearance of sulbactam from the body and the estimated clearance of creatinine (CK). In patients with terminal renal insufficiency, a significant increase in T1 / 2 of sulbactam was found (an average of 6.9 and 9.7 hours in various studies). Hemodialysis caused significant changes in T1 / 2 total clearance from the body and Vd of sulbactam.At the same time, no significant changes in the pharmacokinetics of cefoperazone in patients with renal insufficiency have been identified. T1 / 2 of cefoperazone decreases somewhat during hemodialysis.
    The pharmacokinetics of cefoperazone sulbactam has been studied in elderly people with renal insufficiency and impaired liver function. In comparison with healthy volunteers, an increase in the duration of T1 / 2-decreased clearance and an increase in Vd of both sulbactam and cefoperazone. The pharmacokinetics of sulbactam correlated with the degree of impaired renal function, and the pharmacokinetics of cefoperazone - with a degree of impaired hepatic function.
    As cefoperazone is actively excreted with bile, then T1 / 2 of cefoperazone usually lengthens, and kidney excretion is increased in patients with liver diseases and / or biliary tract obstruction. Even with a serious violation of liver function in the bile, the therapeutic concentration of cefoperazone is reached, and aT1 / 2 increases only 2-4 times. In studies in children, no significant changes in the pharmacokinetic parameters of the components of cefoperazop + sulbactam were found in comparison with those in adults.The average T1 / 2 sulbactam in children ranged from 0.91 to 1.42 h, cefoperazone from 1.44 to 1.88 h.
    Indications:
    Infectious and inflammatory diseases caused by microorganisms sensitive to the preparations:

    - infections of the respiratory tract:

    - intra-abdominal infections (including peritonitis, cholecystitis, etc.);

    - septicemia:

    - bacterial meningitis;

    - infections of the skin and soft tissues;

    - infection of bones and joints;

    - infections of the pelvic organs:

    - urinary tract infection (including gonorrhea).
    Contraindications:Hypersensitivity to cefoperazone, sulbactam, penicillins and other cephalosporins.
    Carefully:With violations of kidney and liver function, colitis (and so on in the anamnesis), premature newborns.
    Pregnancy and lactation:The use of the drug during pregnancy is possible only if the intended benefit to the mother exceeds the potential risk to the fetus. If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.
    Dosing and Administration:
    Intravenous (jet and drip), intramuscularly.
    Adults - 1-2 g of the drug every 12 hours. In severe infections, the daily dose of cefoperazone + sulbactam can be increased to 8 g with a 1: 1 component ratio (ie 4 g of cefoperazone). Patients receiving cefoperazone + sulbactam in a ratio of 1: 1, additional administration of cefoperazone may be required. The dose should be divided into equal parts and administered every 12 hours.
    The recommended maximum daily dose of sulbactam is 4 g.
    Application for renal dysfunction
    In patients with SC 15-30 ml / min, the maximum dose of sulbactam is I g every 12 hours (maximum daily dose of sulbactam 2 g), and in patients with QC less than 15 ml / min the maximum dose of sulbactam is 500 mg every 12 hours (maximum daily dose of sulbactam I g). In severe infections, additional administration of cefoperazone may be required.
    The pharmacokinetics of sulbactam significantly changes during hemodialysis, the half-life of cefoperazone from serum decreases slightly, so the drug should be administered after dialysis.
    Application for violations of liver function
    If regular monitoring of serum concentration of cefoperazone is not performed, the maximum daily dose should not exceed 2 g.
    Use in children
    Children cefoperazone + sulbactam it is recommended to use in the following daily doses:

    Ratio

    cefoperazone + sulbactam (mg / kg / day)

    Cefoperazone

    dose (mg / kg / day)

    sulbactam

    dose (mg / kg / day)

    1:1

    40-8O

    20-40

    20-40


    The dose should be divided into equal parts and administered every 6-12 hours.

    For serious or refractory infections, these dosages can be increased to 160 mg / kg / day for a 1: 1 component ratio. The daily dose is divided into 2-4 equal parts. If it is necessary to introduce more than 80 mg / kg / day, calculated on the activity of cefoperazone, an increase in the dose is achieved due to the additional administration of cefoperazone.

    PChanging the the newborns

    In newborns be administered every 12 hours. The maximum daily dose of sulbactam in children should not exceed 80 mg / kg / day during the first week of life of the drug. A method for preparing solutions of a parenteral atchange

    Breeding:

    Total dose, g

    The equivalent dose cefoperazone + sulbactam, g

    Volume of solvent, ml

    Maximum final concentration, mg / ml









    0.5

    0.25 g 0.25

    1,7

    125 + 125

    1,0

    0.5 + 0.5

    3.4

    125 + 125

    2.0

    1,0 + 1.0

    6.7

    125 + 125

    Intramuscular administration:

    Sterile water for injection is used for dissolution (see table). If the drug is administered at a concentration in excess of 250 mg / ml, it is recommended to prepare the solution using lidocaine. Dilution is carried out in 2 stages - in a vial containing 0.5 g of the drug,add 0.65 ml of sterile water for injection (in a vial containing 1 g of the drug - 1.3 ml, in a vial containing 2 g - 2.6 ml), agitate until completely dissolved, and then add 0.2 ml of a 2% solution of lidocaine hydrochloride (per vial , containing 1 g of the drug - 0.4 ml, in a vial containing 2 g - 0.8 ml). The final solution will contain in 1 ml of a 0.5% solution of lidocaine hydrochloride about 250 mg of cefoperazone and about 250 mg of sulbactam.

    ATnutritional administration:

    For IV introduction, the contents of the vial are dissolved in an adequate volume (see table) of 5% dextrose solution, 0.9% solution NaCL 5% dextrose solution in 0.225% solution NaCl, 5% dextrose solution in 0.9% solution NaCl or sterile water for injection, and injected for 3 minutes.

    For IV infusion introduction dissolve, as mentioned above, then dilute to 20-100 ml with the same solvent and injected for 15-60 minutes:

    Preparation of the solution using Ringer's lactate.

    Since Ringer's lactate is not suitable for initial dilution, the solution is prepared in two steps: first use a sterile injectable oxal (see table) and then dilute the resulting solution with Ringer's lactate solution to a 5 mg / ml sulbactam concentration. Infusion is carried out for 15-60 minutes.

    Side effects:

    From the side cecardiovascular system: arterial hypotension

    From the gastrointestinal tract: diarrhea, nausea, vomiting, pseudomembranous colitis.

    Allergic reactions: maculopapular rash, hives, itching, Stevens-Johnson syndrome, anaphylactic shock.

    The system of hematopoiesis: bleeding (vitamin K deficiency), a decrease in the number of neutrophils. With long-term treatment, reversible neutropenia, a decrease in hemoglobin and hematocrit, transient eosinophilia, thrombocytopenia, leukopenia, hypoprothrombinemia develops.

    Local reactions: sometimes, after a / m injection, there is transient pain and burning at the injection site. With iv administration of the drug, phlebitis may develop at the site of administration. Laboratory indicators: hyperkreatininemia, transient increase in "liver" transaminases, alkaline phosphatase and bilirubin in blood serum, hematuria, false-positive Coombs test. When using a solution of Benedict or Fäding, a false-positive reaction to glucose in the urine can be observed.

    Other: headache, fever, chills, vasculitis.

    Overdose:
    Information on acute toxicity of cefoperazone and sulbactam is limited.Symptoms: neurological disorders, including convulsions.
    Treatment: symptomatic, hemodialysis is effective, especially in patients with impaired renal function.
    Interaction:Solutions Bakderazona and aminoglycosides should not be directly mixed, given the physical incompatibility between them. If combined therapy with Bakperazone and aminoglycosides is carried out, the two drugs are administered by successive infusions using separate secondary catheters and the primary catheter is washed with an adequate solution (5% dextrose solution, 0.9% NaCl solution, 5% dextrose solution in 0.225% NaCl solution, 5% dextrose solution in 0.9% NaCl solution or sterile water for injections) between the administration of drug doses. The intervals between the administration of Bakperazone and aminoglycoside during the day should be as large as possible. Incompatible with Ringer's solution, 2% lidocaine hydrochloride solution (initial use of water for injection leads to the formation of a compatible mixture). When using ethanol during treatment with the drug and for up to 5 days after its administration, reactions characterized by "hot flashes", sweating, headache and tachycardia were recorded.Patients should be warned about the possibility of a disulfiram-like effect when using ethanol against the background of drug treatment.
    Special instructions:
    In patients who received beta-lactam antibiotics, incl. cephalosporins, cases of development of serious reactions of hypersensitivity (anaphylactic), which sometimes led to death, are described. The risk of developing such reactions is higher in those patients who have a history of hypersensitivity reactions to various allergens. In case of an allergic reaction, it is necessary to cancel the drug and prescribe adequate therapy. Anaphylactic reactions require urgent epinephrine, intravenous glucocorticosteroids and airway patency, including intubation, are indicated by indications oxygen. With severe liver and biliary tract diseases and, especially, combined with impaired renal function, correction of the dosing regimen is necessary. In patients with hepatic or renal insufficiency, continuous monitoring of serum concentration of cefoperazone and correction of its dose are necessary if necessary.
    In the treatment of cefoperazonom in rare cases, a vitamin K deficiency developed. Its cause is probably suppression of normal intestinal microflora, which synthesizes this vitamin. The risk group can include patients receiving malnutrition, patients with malabsorption (for example, in cystic fibrosis) and long-term in / in artificial feeding. In such cases, as well as in patients receiving anticoagulants, it is necessary to monitor prothrombin time and if there is an indication to prescribe vitamin K.
    With prolonged treatment, excessive growth of insensitive microorganisms can be observed.
    With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys, liver and hematopoiesis system.
    Effect on the ability to drive transp. cf. and fur:
    Experience in the use of the drug in clinical practice indicates that deterioration
    the ability to manage vehicles and mechanisms during the period of drug use is unlikely.
    Form release / dosage:
    Powder for solution for intravenous and intramuscular injection 250 mg + 250 mg; 0.5 g + 0.5 g; 1.0 g + 1.0 g.
    Packaging:
    For 500 mg, 1 g or 2 g of active substance in a glass colorless bottle, sealed with sulfur butyl rubber stopper, coated with an aluminum cap with additional packaging in the form of a plastic cap; 1 bottle together with instructions for use in a pack of cardboard or 50 bottles (for hospitals), along with instructions for use are placed in a box of cardboard.
    Storage conditions:Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.
    Shelf life:
    3 years. Do not use after the expiration date stated on the package.
    The prepared injectable solution is suitable for use for 24 hours at a temperature of no higher than 25 ° C.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-009612/09
    Date of registration:30.11.2009
    The owner of the registration certificate:Jepak InternationalJepak International India
    Manufacturer: & nbsp
    Representation: & nbspJEPAK INTERNATIONALJEPAK INTERNATIONALRussia
    Information update date: & nbsp30.10.2015
    Illustrated instructions
      Instructions
      Up